BioTuesdays

Category - Features

DURECT awaiting Pfizer meeting with FDA on Remoxy

DURECT (NASDAQ:DRRX) has a lot riding on a meeting in late March between its marketing partner, Pfizer, and the FDA to discuss resubmitting a new drug application for its lead pain drug, Remoxy, as a tamper-resistant...

In conversation with Will Zerhouni

As CEO of closely held i3 Analytics, Will Zerhouni founded the company on the belief that data analytics should be for everyone in biopharma, not just major players with deep pockets. As a former associate at Covington...

Prima BioMed to get key CVac data in second half

After posting positive trends in interim data, Prima BioMed (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) is focusing on two final data readouts in the second half this year from a Phase 2b clinical trial of its CVac cancer...

Trimel in pre-NDA meeting with FDA next month

Fresh from reporting positive Phase 3 results for its CompleoTRT intranasal gel for “Low T”, Trimel Pharmaceutics (TSX:TRL) plans to meet with the FDA in February to discuss its plans for filing a new drug application...

Subscribe

Sign up to our weekly BioTuesdays newsletter.